- Guide to PHARMACOLOGY
Synonyms: ASN-002 | ASN002 | example 189 [WO2013028818A1]
Compound class: Synthetic organic
Comment: Gusacitinib (ASN002) is an orally bioavailable dual spleen tyrosine kinase (SYK)/pan Janus kinase (JAK) inhibitor that is being developed by Asana BioSciences. It is being evaluated for clinical efficacy in inflammatory and oncology settings. Not to be confused with Ascend Biopharmaceuticals immuno-oncology lead ASN-002, which is an engineered virus that expresses IFN-γ.
Gusacitinib is one of the chemical structures (example 189) claimed in Asana Biosciences' patent WO2013028818A1 .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|ASN002 simultaneously inhibits two signalling pathways that impinge on the inflammatory response. This dual action is predicted to provide improved clinical efficacy. ASN002 has completed a Phase 2 evaluation in patients with atopic dermatitis (NCT03139981).|